Clinical trials in Corbeil Essonnes – page 92

3 332 clinical trials in Corbeil Essonnes, France across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in FranceEssaisCliniques.fr

Corbeil Essonnes at a glance

3 332

clinical trials

Research sites1

Quick filters

3 332 trials in Corbeil Essonnes

Open in trial search

Systemic lupus erythematosus

Recruiting

Study on the Effects of Abacavir and Lamivudine in Patients with Systemic Lupus Erythematosus with Low Disease Activity

Registered drugNo placebo

Study on the Effects of Abacavir and Lamivudine in Patients with Systemic Lupus Erythematosus with Low Disease Activity

Registered drugNo placebo

France

Participants:0–17 years · 18–64 years · 65+ years
Substances:Abacavir
Sponsor:Hospices Civils De Lyon

Contact Research Centre

Behcet's syndrome

Recruiting

Study on Apremilast for Treating Oral Ulcers in Children with Behçet's Disease

Investigational

Study on Apremilast for Treating Oral Ulcers in Children with Behçet's Disease

Investigational

France

Participants:0–17 years
Substances:Apremilast
Sponsor:Amgen Inc.

Contact Research Centre

Myasthenia gravis

Recruiting

Study on Nipocalimab for Adults with Generalized Myasthenia Gravis

Investigational

Study on Nipocalimab for Adults with Generalized Myasthenia Gravis

Investigational

France

Participants:18–64 years · 65+ years
Substances:Nipocalimab
Sponsor:Janssen Cilag International

Contact Research Centre

Colon cancer

Recruiting

Study on the Effectiveness of Chemotherapy with Folinic Acid, Fluorouracil, and Irinotecan for Patients with Stage III Colon Cancer After Surgery

Registered drugNo placebo

Study on the Effectiveness of Chemotherapy with Folinic Acid, Fluorouracil, and Irinotecan for Patients with Stage III Colon Cancer After Surgery

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Centre Hospitalier Universitaire De Dijon

Contact Research Centre

Glomerulonephritis membranoproliferative

Recruiting

Study on the Effects of Iptacopan in Patients with Idiopathic Membranoproliferative Glomerulonephritis (IC-MPGN)

Investigational

Study on the Effects of Iptacopan in Patients with Idiopathic Membranoproliferative Glomerulonephritis (IC-MPGN)

Investigational

France

Participants:0–17 years · 18–64 years
Substances:Iptacopan
Sponsor:Novartis Pharma AG

Contact Research Centre

Acute respiratory failure

Recruiting

Study on Weaning Patients with Acute Respiratory Failure from High-Flow Nasal Oxygen Therapy Using Oxygen

Registered drugNo placebo

Study on Weaning Patients with Acute Respiratory Failure from High-Flow Nasal Oxygen Therapy Using Oxygen

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Oxygen
Sponsor:Centre Hospitalier Regional Universitaire De Tours

Contact Research Centre

Methylmalonic acidaemia

Recruiting

Study on Long-Term Safety of mRNA-3705 for Patients with Methylmalonic Acidemia (MMA)

Registered drugNo placebo

Study on Long-Term Safety of mRNA-3705 for Patients with Methylmalonic Acidemia (MMA)

Registered drugNo placebo

France

Participants:0–17 years · 18–64 years
Substances:Dexamethasone
Sponsor:Moderna Inc.

Contact Research Centre

Breast cancer

Recruiting

Study on Tucatinib, Capecitabine, and Trastuzumab for Patients with HER2-Positive Breast Cancer and Leptomeningeal Metastases

Registered drugNo placebo

Study on Tucatinib, Capecitabine, and Trastuzumab for Patients with HER2-Positive Breast Cancer and Leptomeningeal Metastases

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:Unicancer

Contact Research Centre

Plasma cell myeloma

Recruiting

Study on Linvoseltamab and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma Who Have Not Yet Received Treatment

Registered drugNo placebo

Study on Linvoseltamab and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma Who Have Not Yet Received Treatment

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Dexamethasone
Sponsor:Regeneron Pharmaceuticals Inc.

Contact Research Centre

Small cell lung cancer+1

Recruiting

Study on BI 764532 for Patients with Relapsed or Refractory Small Cell Lung Cancer and Other Neuroendocrine Carcinomas

InvestigationalNo placebo

Study on BI 764532 for Patients with Relapsed or Refractory Small Cell Lung Cancer and Other Neuroendocrine Carcinomas

InvestigationalNo placebo

France

Participants:18–64 years · 65+ years
Sponsor:Boehringer Ingelheim International GmbH

Contact Research Centre

Acute lymphocytic leukaemia+4

Recruiting

Study on Trametinib, Dexamethasone, Cyclophosphamide, and Cytarabine for Children with Relapsed or Refractory Blood Cancer

Registered drugNo placebo

Study on Trametinib, Dexamethasone, Cyclophosphamide, and Cytarabine for Children with Relapsed or Refractory Blood Cancer

Registered drugNo placebo

France

Participants:0–17 years · 18–64 years
Substances:Trametinib
Sponsor:Prinses Maxima Centrum voor Kinderoncologie B.V.

Contact Research Centre

Pulmonary arterial hypertension

Recruiting

Study on the Effectiveness and Safety of Treprostinil and Drug Combination for Patients with Pulmonary Arterial Hypertension (Group I)

Registered drugNo placebo

Study on the Effectiveness and Safety of Treprostinil and Drug Combination for Patients with Pulmonary Arterial Hypertension (Group I)

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Treprostinil
Sponsor:Aop Orphan Pharmaceuticals GmbH

Contact Research Centre

Other cities in France

The busiest research cities in the country

All 366 cities in France

Clinical research in Corbeil Essonnes

What the registry says about research in the country

01 Diabetes and Metabolic Disorders

Clinical research focusing on novel treatments for Type 1 and Type 2 Diabetes, particularly investigating therapies like tirzepatide for glycemic control and cardiovascular outcomes in patients with obesity and diabetes.

Glycemic Control Studies
Cardiovascular Risk Management
Weight Management Therapies

02 Hematologic Malignancies

Groundbreaking trials in Multiple Myeloma treatment, evaluating combinations of targeted therapies including elranatamab, lenalidomide, and daratumumab for newly diagnosed and relapsed cases.

Novel Drug Combinations
Maintenance Therapy Optimization
Minimal Residual Disease Studies

03 Inflammatory and Autoimmune Conditions

Research examining innovative treatments for Immune Thrombocytopenia, Polymyalgia Rheumatica, and Lupus Nephritis, focusing on targeted therapies and steroid-sparing approaches.

Immunotherapy Development
Alternative Treatment Strategies
Disease Management Protocols

Back to France All countries